{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:24:21Z","timestamp":1794306261330,"version":"4.9.0"},"reference-count":40,"publisher":"BMJ","issue":"1","funder":[{"name":"Dutch Prinses Beatrix Spierfonds","award":["W.OR16-18"],"award-info":[{"award-number":["W.OR16-18"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to determine treatment response and whether it is associated with antibody titre change in patients with autoimmune nodopathy (AN) previously diagnosed as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and to compare clinical features and treatment response between AN and CIDP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum IgG antibodies to neurofascin-155 (NF155), contactin-1 (CNTN1) and contactin-associated protein 1 (CASPR1) were detected with cell-based assays in patients diagnosed with CIDP. Clinical improvement was determined using the modified Rankin scale, need for alternative and\/or additional treatments and assessment of the treating neurologist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We studied 401 patients diagnosed with CIDP and identified 21 patients with AN (10 anti-NF155, 6 anti-CNTN1, 4 anti-CASPR1 and 1 anti-NF155\/anti-CASPR1 double positive). In patients with AN ataxia (68% vs 28%, p=0.001), cranial nerve involvement (34% vs 11%, p=0.012) and autonomic symptoms (47% vs 22%, p=0.025) were more frequently reported; patients with AN improved less often after intravenous immunoglobulin treatment (39% vs 80%, p=0.002) and required additional\/alternative treatments more frequently (84% vs 34%, p&lt;0.001), compared with patients with CIDP. Antibody titres decreased or became negative in patients improving on treatment. Treatment withdrawal was associated with a titre increase and clinical deterioration in four patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Distinguishing CIDP from AN is important, as patients with AN need a different treatment approach. Improvement and relapses were associated with changes in antibody titres, supporting the pathogenicity of these antibodies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2023-331378","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T13:20:21Z","timestamp":1698240021000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort"],"prefix":"10.1136","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7770-8475","authenticated-orcid":false,"given":"Merel C","family":"Broers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"Wieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"Erdag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemre","family":"G\u00fcrlek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bunschoten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1003-500X","authenticated-orcid":false,"given":"Krista","family":"Kuitwaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juna M","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claire Y","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariska MP","family":"Nagtzaam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne C","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Paunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco WJ","family":"Schreurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinta","family":"Lleix\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1553-2224","authenticated-orcid":false,"given":"Lorena","family":"Mart\u00edn-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-4305","authenticated-orcid":false,"given":"Elba","family":"Pascual-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-2458","authenticated-orcid":false,"given":"Bart C","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9563-4860","authenticated-orcid":false,"given":"Ruth","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-3840","authenticated-orcid":false,"given":"Maarten J","family":"Titulaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"2023121402451063000_95.1.52.1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959"},{"key":"2023121402451063000_95.1.52.2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12364","article-title":"Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"25","author":"Van den Bergh","year":"2020","journal-title":"J Peripher Nerv Syst"},{"key":"2023121402451063000_95.1.52.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30144-9"},{"key":"2023121402451063000_95.1.52.4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309697"},{"key":"2023121402451063000_95.1.52.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002418"},{"key":"2023121402451063000_95.1.52.6","doi-asserted-by":"crossref","unstructured":"Cortese A , Lombardi R , Briani C , et al . Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG Isotype. Neurol Neuroimmunol Neuroinflamm 2020;7:e639. doi:10.1212\/NXI.0000000000000639","DOI":"10.1212\/NXI.0000000000000639"},{"key":"2023121402451063000_95.1.52.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10041-z"},{"key":"2023121402451063000_95.1.52.8","doi-asserted-by":"crossref","unstructured":"Vural A , Doppler K , Meinl E . Autoantibodies against the node of ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance. Front Immunol 2018;9:1029. doi:10.3389\/fimmu.2018.01029","DOI":"10.3389\/fimmu.2018.01029"},{"key":"2023121402451063000_95.1.52.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02930.x"},{"key":"2023121402451063000_95.1.52.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.206599"},{"key":"2023121402451063000_95.1.52.11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309042"},{"key":"2023121402451063000_95.1.52.12","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/ene.14742","article-title":"Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Kuitwaard","year":"2021","journal-title":"Eur J Neurol"},{"key":"2023121402451063000_95.1.52.13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/ene.14501","article-title":"Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Kuitwaard","year":"2021","journal-title":"Eur J Neurol"},{"key":"2023121402451063000_95.1.52.14","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/ene.14796","article-title":"Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Broers","year":"2021","journal-title":"Eur J Neurol"},{"key":"2023121402451063000_95.1.52.15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e07d14"},{"key":"2023121402451063000_95.1.52.16","doi-asserted-by":"crossref","unstructured":"Lieverloo GG Al-Soudi A A, Wieske L , et al . B-cell and T-cell receptor repertoire in chronic inflammatory Demyelinating polyneuropathy, a prospective cohort study. J Peripher Nerv Syst 2023:69\u201378. doi:10.1111\/jns.12533","DOI":"10.1111\/jns.12533"},{"key":"2023121402451063000_95.1.52.17","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/brain\/awac054","article-title":"Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"145","author":"Adrichem","year":"2022","journal-title":"Brain"},{"key":"2023121402451063000_95.1.52.18","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12296"},{"key":"2023121402451063000_95.1.52.19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318208824b"},{"key":"2023121402451063000_95.1.52.20","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4598(200009)23:9<1393::AID-MUS10>3.0.CO;2-O"},{"key":"2023121402451063000_95.1.52.21","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1468-1331.2012.03851.x","article-title":"Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study","volume":"20","author":"Vanhoutte","year":"2013","journal-title":"Eur J Neurol"},{"key":"2023121402451063000_95.1.52.22","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880141111"},{"key":"2023121402451063000_95.1.52.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92644-2"},{"key":"2023121402451063000_95.1.52.24","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.19.5.604"},{"key":"2023121402451063000_95.1.52.25","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz094"},{"key":"2023121402451063000_95.1.52.26","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq213"},{"key":"2023121402451063000_95.1.52.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7408-6"},{"key":"2023121402451063000_95.1.52.28","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1212\/WNL.0000000000003300","article-title":"The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies","volume":"87","author":"Lilleker","year":"2016","journal-title":"Neurology"},{"key":"2023121402451063000_95.1.52.29","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000725"},{"key":"2023121402451063000_95.1.52.30","doi-asserted-by":"crossref","unstructured":"Querol L , Rojas-Garc\u00eda R , Diaz-Manera J , et al . Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015;2:e149. doi:10.1212\/NXI.0000000000000149","DOI":"10.1212\/NXI.0000000000000149"},{"key":"2023121402451063000_95.1.52.31","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1212\/WNL.0000000000004773","article-title":"Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies","volume":"90","author":"Burnor","year":"2018","journal-title":"Neurology"},{"key":"2023121402451063000_95.1.52.32","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/mus.26010","article-title":"Neurofascin-155 IgG4 neuropathy: pathophysiological insights, spectrum of clinical severity and response to treatment","volume":"57","author":"Garg","year":"2018","journal-title":"Muscle Nerve"},{"key":"2023121402451063000_95.1.52.33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982"},{"key":"2023121402451063000_95.1.52.34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2018.10.008","article-title":"The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy","volume":"55","author":"Hale","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"2023121402451063000_95.1.52.35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a1aa9c"},{"key":"2023121402451063000_95.1.52.36","doi-asserted-by":"crossref","unstructured":"Carrera-Garc\u00eda L , Natera-de Benito D , Lleix\u00e0 C , et al . Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child. Neurol Neuroimmunol Neuroinflamm 2019;6:e602. doi:10.1212\/NXI.0000000000000602","DOI":"10.1212\/NXI.0000000000000602"},{"key":"2023121402451063000_95.1.52.37","doi-asserted-by":"crossref","unstructured":"De Simoni D , Ricken G , Winklehner M , et al . Antibodies to nodal\/paranodal proteins in paediatric immune-mediated neuropathy. Neurol Neuroimmunol Neuroinflamm 2020;7:e763. doi:10.1212\/NXI.0000000000000763","DOI":"10.1212\/NXI.0000000000000763"},{"key":"2023121402451063000_95.1.52.38","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv054"},{"key":"2023121402451063000_95.1.52.39","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001833"},{"key":"2023121402451063000_95.1.52.40","doi-asserted-by":"crossref","unstructured":"Dalakas MC . Igg4-mediated neurologic autoimmunities: understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies. Neurol Neuroimmunol Neuroinflamm 2022;9:e1116. doi:10.1212\/NXI.0000000000001116","DOI":"10.1212\/NXI.0000000000001116"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-331378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T05:48:30Z","timestamp":1702532910000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-331378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,14]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/jnnp-2023-331378"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-331378","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]}}}